VTCN1
(V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))
Type de proteíne
Recombinant
Origine
Humain
Source
HEK-293 Cells
Purification/Conjugué
Cette VTCN1 protéine est marqué à la His-Avi Tag,Biotin.
Séquence
Phe29-Ala258
Pureté
> 95% as determined by Tris-Bis PAGE,> 95% as determined by HPLC
Stérilité
0.22 μm filtered
niveau d'endotoxine
Less than 1EU per μg by the LAL method.
Biological Activity Comment
Immobilized Anti-B7-H4 Antibody, hFc Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human B7-H4, His Tag with the EC50 of 24.3ng/ml determined by ELISA. See testing image for detail.
VTCN1
Origine: Humain
Hôte: Escherichia coli (E. coli)
Recombinant
Greater than 90 % by SDS-PAGE gel analyses
WB, ELISA
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.
Buffer
Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 5 % trehalose is added as protectant before lyophilization.
Stock
4 °C,-80 °C
Stockage commentaire
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Date de péremption
12 months
Antigène
VTCN1
(V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))
B7h4 Protein, B7s1 Protein, B7x Protein, BC032925 Protein, B7-H4 Protein, B7H4 Protein, B7S1 Protein, B7X Protein, B7h.5 Protein, PRO1291 Protein, VCTN1 Protein, RGD1311204 Protein, V set domain containing T cell activation inhibitor 1 L homeolog Protein, V-set domain containing T cell activation inhibitor 1 Protein, V-set domain containing T-cell activation inhibitor 1 Protein, V set domain containing T cell activation inhibitor 1 Protein, vtcn1.L Protein, VTCN1 Protein, vtcn1 Protein, Vtcn1 Protein
Sujet
B7H4, B7-H4, B7S1, B7h.5, B7x, FLJ22418, VTCN1, PRO1291,B7-H4, also known as B7x and B7S1, is a 50-80 kDa glycosylated member of the B7 family of immunomodulatory proteins.B7-H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status.
Poids moléculaire
28.2 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.